Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer

External-Beam Radiotherapy in the Management of Carcinoma of the Prostate

“…20 This grade effect has also been demonstrated in patients with otherwise favorable prognostic factors of early clinical stage (T1-T2) and initial PSA level less than 15 ng/mL, using freedom from PSA progression as an end point. 22 Since PSA testing became widespread beginning in the early 1990s, it has become apparent that the PSA level at diagnosis is a more significant independent prognostic variable than grade [22][23][24] and that the posttreatment PSA levels represent the standard for measurement of treatment effectiveness and patient cure. 25 Differences range between 10% and 40% for outcomes, based on reports of clinical control vs PSA findings.…”

Update on the treatment of prostate cancer with external beam irradiation

“…Current results of treatment with conventional doses of radiation (<70 Gy) show similar rates of bNED control when patients are stratified by pretreatment PSA levels [35,40,[45][46][47][48]. However, as pretreatment PSA levels increase, rates of bNED control decrease.…”

Braquiterapia de alta taxa de dose no tratamento do carcinoma da próstata: análise da toxicidade aguda e do comportamento bioquímico

“…Notamos que a maioria é de risco intermediário (44%), enquanto 33% são de risco baixo e 22% são de alto risco. Os resultados poderiam ser mais satisfatórios se tivéssemos maior número de pacientes no baixo risco (10) . Todas as variáveis analisadas não mostraram nenhuma significância em relação ao controle bioquímico.…”